Chondrosarcoma: lines of therapy
5 standard-of-care settings across 3 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Early / localised
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Conventional grade 2 to 3, resectable | Wide en bloc resection with limb-salvage or pelvic reconstruction in a bone sarcoma centre; radiotherapy only for positive margins. | 93 | ||
| All comers | Skull base and spine, incompletely resectable | Maximal safe surgery followed by high-dose proton or carbon-ion radiotherapy. | 93 |
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| IDH | Advanced IDH1-mutant conventional | Ivosidenib within the CHONQUER phase 3 trial or compassionate access; no approved systemic therapy. | 93 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Atypical cartilaginous tumour of the limbs | Intralesional curettage with local adjuvant, or observation of asymptomatic lesions; no chemotherapy or radiotherapy. | 63 | ||
| All comers | Dedifferentiated and mesenchymal | Surgery plus osteosarcoma-type (doxorubicin, cisplatin) or Ewing-type (doxorubicin, ifosfamide) chemotherapy, benefit uncertain. | 81 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.